home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

p53 independent cancer drug

 
  October, 3 2000 1:48
your information resource in human molecular genetics
 
     
Nature Medicine

UCSF finding suggests mechanism of experimental cancer drug, hinting at broader application for the drug, a modified cold virus UC San Francisco researchers may have discovered why the experimental anti-cancer drug Onyx-015 works more broadly than had been expected, a finding that could solidify and expand use of the drug and which reveals a potential new target for therapy that could prompt the development of other cancer drugs.
Onyx Pharmaceuticals, Inc.
Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
15-476-2557
University of California, San Francisco


Message posted by: Wouter Kalle

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.